In vitro assays demonstrated its robust cytotoxicity against CD19+CD133+ and CD19−CD133+ B cells, which could help reduce the subsequent lineage switch in MLL-r B-ALL [278]. The gene discussed is PROM1; the disease is acute lymphoblastic leukemia.